MétaCan
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
→
Sort
Language
Type
Field
Venue
Topic
Health Systems, Economic Evaluations, Quality of Life
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

6,862 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
6,862 works in the cohort · of 4,299,418page 84 of 138

Labels cover 97 of 6,862 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 6,862 of 6,862 works in this cohort. Predictions are machine_predicted_unvalidated. The Gemma side is a direct model label for every work (title-only); the Codex side is a distilled, calibrated classifier. Candidate is the union; consensus is the intersection.

affaboutunlabeled
Docetaxel plus cyclophosphamide is cost-effective compared to doxorubicin plus cyclophosphamide, based on an economic analysis of US oncology trial 9735: additional rationale to avoid anthracyclines in the adjuvant treatment of operable breast cancer?.
S. Verma, Nicole Mittmann, Lisa Bernard, Matthew J. Thompson, Boon Yeow Daniel Chan, Lina Asmar +1 more
2009· article· en· Cancer Research· Economics, Econometrics and Finance
machine prediction:candidate · noneconsensus · none
1
citations
fundno affunlabeled
Multiple Cost Optimisation for Alzheimer's Disease Diagnosis
Niamh McCombe, Xuemei Ding, Girijesh Prasad, David P. Finn, Stephen Todd, Paula L. McClean +2 more
2022· article· en· 2022 44th Annual International Conference of the IEEE Engineering in Medicine & Biology Society (EMBC)· Economics, Econometrics and Finance
machine prediction:candidate · noneconsensus · none
1
citations
aboutno affunlabeled
OP78 Picturing ELSI+: Mapping Ethical, Legal, Social And Value Issues
Murray Krahn, Karen E. Bremner, Claire de Oliveira, N. Almeida, Fiona Clement, Diane Lorenzetti +3 more
2019· article· en· International Journal of Technology Assessment in Health Care· Economics, Econometrics and Finance
machine prediction:candidate · noneconsensus · none
1
citations
affaboutunlabeled
Publicly funded clinical research in Canada
İlke Akpinar, Dat T. Tran, Philip Jacobs
2019· article· en· Healthcare Management Forum· Economics, Econometrics and Finance
machine prediction:candidate · metaresearchconsensus · none
1
citations
affvenueunlabeled
Surrogate Endpoints in Colorectal Cancer
G Browman, Amil M. Shah, Jean-Pierre Ayoub, Ralph Wong, Jean A. Maroun, Gerald Batist
2005· article· en· Current Oncology· Economics, Econometrics and Finance
machine prediction:candidate · noneconsensus · none
1
citations
aboutno affunlabeled
Promoting economic value in public health
Reiner Leidl
2008· editorial· en· European Journal of Public Health· Economics, Econometrics and Finance
machine prediction:candidate · noneconsensus · none
1
citations

How this was built: Screen · Findings · About